Ascension Seton Medical Center
- Type
- Teaching hospital
- Where
- Austin, TX
- Medicare CCN
- 450056
- Received
- $604,333 in 467 records, 2021 ($26,014 general, $578,319 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: ASCENSION SETON MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 23 | $26,014 |
| 2021 | Research payment | 444 | $578,319 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 47 | $224,856 | 2021 |
| VERTEX PHARMACEUTICALS INCORPORATED | 6 | $89,810 | 2021 |
| Abbott Laboratories | 34 | $82,490 | 2021 |
| Aimmune Therapeutics, Inc. | 283 | $75,380 | 2021 |
| Terumo Medical Corporation | 2 | $25,941 | 2021 |
| Boston Scientific Corporation | 10 | $20,235 | 2021 |
| Esperion Therapeutics, Inc. | 51 | $20,027 | 2021 |
| JAZZ PHARMACEUTICALS INC. | 1 | $15,000 | 2021 |
| Travere Therapeutics, Inc. | 5 | $14,095 | 2021 |
| AngioDynamics, Inc. | 1 | $13,000 | 2021 |
| Medtronic, Inc. | 2 | $11,500 | 2021 |
| Merge Healthcare Incorporated | 16 | $5,806 | 2021 |
| Mallinckrodt Hospital Products Inc. | 3 | $2,600 | 2021 |
| Stryker Corporation | 2 | $1,500 | 2021 |
| HEARTFLOW, INC. | 2 | $1,000 | 2021 |
| Merit Medical Systems Inc | 1 | $1,000 | 2021 |
| UCB SA | 1 | $90 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 444 | $578,319 |
| Education | 1 | $13,000 |
| Food and Beverage | 16 | $5,806 |
| Charitable Contribution | 1 | $5,000 |
| Space rental or facility fees (teaching hospital only) | 4 | $1,207 |
| Debt forgiveness | 1 | $1,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | AngioDynamics, Inc. | $13,000 | Education | In-kind items and services | Solero Device, Oncology | 2021 | |
| 2021-12-31 | Abbott Laboratories | $622 | Research payment | In-kind items and services | HeartMate 3 Left Ventricular Assist Device Device, Heart Failure | PHP SHIELD II | 2021 |
| 2021-12-31 | Aimmune Therapeutics, Inc. | $21 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-12-27 | Esperion Therapeutics, Inc. | $96 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-27 | Esperion Therapeutics, Inc. | $2 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $3,272 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $688 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $539 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $539 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-10 | Abbott Laboratories | $269 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-12-09 | Esperion Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-08 | Abbott Laboratories | $1,104 | Research payment | Cash or cash equivalent | Confirm Rx Device, Cardiac Rhythm Management | Confirm Rx Insertable Cardiac Monitor SMART Registry | 2021 |
| 2021-12-08 | Aimmune Therapeutics, Inc. | $2 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-12-06 | Boston Scientific Corporation | $1,033 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | HI PEITHO | 2021 |
| 2021-12-06 | Boston Scientific Corporation | $940 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | HI PEITHO | 2021 |
| 2021-12-06 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | HI PEITHO | 2021 |
| 2021-12-01 | Aimmune Therapeutics, Inc. | $1,147 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-12-01 | Aimmune Therapeutics, Inc. | $90 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-11-26 | Abbott Laboratories | $5,000 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent Device, Vascular | 15mm Surgical Mechanical Aortic Valve PAS | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $688 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-18 | Regeneron Pharmaceuticals, Inc. | $13,785 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO < | 2021 |
| 2021-11-17 | Medtronic, Inc. | $11,000 | Research payment | Cash or cash equivalent | FlowMet-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2021 |
| 2021-11-17 | Aimmune Therapeutics, Inc. | $528 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-11-17 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | FlowMet-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2021 |
| 2021-11-15 | Aimmune Therapeutics, Inc. | $90 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-11-15 | Aimmune Therapeutics, Inc. | $3 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-11-10 | Abbott Laboratories | $8,606 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent Device, Vascular | AMPLATZER PFO Occluder Post Approval Study | 2021 |
| 2021-11-10 | Aimmune Therapeutics, Inc. | $555 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-11-10 | Aimmune Therapeutics, Inc. | $20 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-11-05 | Aimmune Therapeutics, Inc. | $4,404 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-11-04 | Abbott Laboratories | $2,800 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial | 2021 |
| 2021-11-04 | Travere Therapeutics, Inc. | $1,200 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2021 |
| 2021-11-04 | Travere Therapeutics, Inc. | $1,200 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2021 |
| 2021-11-04 | Travere Therapeutics, Inc. | $590 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2021 |
| 2021-11-03 | Regeneron Pharmaceuticals, Inc. | $6,196 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-11-03 | Aimmune Therapeutics, Inc. | $975 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-11-01 | Aimmune Therapeutics, Inc. | $884 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-11-01 | Aimmune Therapeutics, Inc. | $555 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-11-01 | Boston Scientific Corporation | $40 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2021 |
| 2021-11-01 | Aimmune Therapeutics, Inc. | $20 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-11-01 | Aimmune Therapeutics, Inc. | $2 | Research payment | Cash or cash equivalent | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 | |
| 2021-10-28 | Abbott Laboratories | $625 | Research payment | Cash or cash equivalent | Dragonfly OCT Device, Vascular | Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II) | 2021 |
| 2021-10-25 | Abbott Laboratories | $105 | Research payment | In-kind items and services | Confirm Rx Device, Cardiac Rhythm Management | Confirm Rx Insertable Cardiac Monitor SMART Registry | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $539 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $539 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-20 | Abbott Laboratories | $4,040 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial | 2021 |
| 2021-10-18 | Boston Scientific Corporation | $276 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | HI PEITHO | 2021 |
| 2021-10-18 | Boston Scientific Corporation | $200 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | HI PEITHO | 2021 |
| 2021-10-13 | Regeneron Pharmaceuticals, Inc. | $2,508 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-10-12 | Esperion Therapeutics, Inc. | $800 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-12 | Merge Healthcare Incorporated | $164 | Food and Beverage | Cash or cash equivalent | cardio Device, Medical Imaging | 2021 | |
| 2021-10-12 | Esperion Therapeutics, Inc. | $3 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-10 | Regeneron Pharmaceuticals, Inc. | $38 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-10-08 | Abbott Laboratories | $2,412 | Research payment | Cash or cash equivalent | Absorb GT1 Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2021 |
| 2021-09-30 | Regeneron Pharmaceuticals, Inc. | $4,383 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-09-28 | Aimmune Therapeutics, Inc. | $1,200 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-09-28 | Merge Healthcare Incorporated | $306 | Food and Beverage | Cash or cash equivalent | cardiology Device, Medical Imaging | 2021 | |
| 2021-09-28 | Aimmune Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-09-27 | Esperion Therapeutics, Inc. | $4,000 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-09-27 | Esperion Therapeutics, Inc. | $250 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-09-23 | UCB SA | $90 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO- AND ACTIVE-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AN | 2021 | |
| 2021-09-22 | Regeneron Pharmaceuticals, Inc. | $45,543 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-09-17 | Abbott Laboratories | $269 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-09-08 | Abbott Laboratories | $1,451 | Research payment | Cash or cash equivalent | Confirm Rx Device, Cardiac Rhythm Management | Confirm Rx Insertable Cardiac Monitor SMART Registry | 2021 |
| 2021-09-08 | Merge Healthcare Incorporated | $73 | Food and Beverage | Cash or cash equivalent | cardio Device, Medical Imaging | 2021 | |
| 2021-09-07 | Aimmune Therapeutics, Inc. | $849 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-09-07 | Merge Healthcare Incorporated | $573 | Food and Beverage (4 payments) | Cash or cash equivalent | cardiology Device, Medical Imaging | 2021 | |
| 2021-09-07 | Aimmune Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-09-07 | Aimmune Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-09-07 | Aimmune Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-09-07 | Aimmune Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-09-07 | Aimmune Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-09-01 | Esperion Therapeutics, Inc. | $1,200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-25 | Abbott Laboratories | $3,678 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial | 2021 |
| 2021-08-24 | Aimmune Therapeutics, Inc. | $1,200 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-24 | Aimmune Therapeutics, Inc. | $1,200 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-24 | Aimmune Therapeutics, Inc. | $1,200 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-24 | Aimmune Therapeutics, Inc. | $791 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-24 | Aimmune Therapeutics, Inc. | $791 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-24 | Aimmune Therapeutics, Inc. | $30 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-24 | Aimmune Therapeutics, Inc. | $30 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-18 | Esperion Therapeutics, Inc. | $32 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-15 | Terumo Medical Corporation | $19,941 | Research payment | Cash or cash equivalent | PROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR | 2021 | |
| 2021-08-12 | Abbott Laboratories | $150 | Research payment | Cash or cash equivalent | Dragonfly OCT Device, Vascular | Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II) | 2021 |
| 2021-08-11 | Abbott Laboratories | $5,048 | Research payment | Cash or cash equivalent | MitraClip System Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study | 2021 |
| 2021-08-11 | Aimmune Therapeutics, Inc. | $1,198 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-11 | Esperion Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-03 | Boston Scientific Corporation | $3,420 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2021 |
| 2021-08-03 | Aimmune Therapeutics, Inc. | $955 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-03 | Aimmune Therapeutics, Inc. | $87 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-03 | Aimmune Therapeutics, Inc. | $30 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-03 | Aimmune Therapeutics, Inc. | $30 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-03 | Aimmune Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-03 | Aimmune Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-08-03 | Aimmune Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-07-28 | Regeneron Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO < | 2021 |
| 2021-07-28 | Regeneron Pharmaceuticals, Inc. | $128 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO < | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $90 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-21 | Abbott Laboratories | $399 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-07-20 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-06 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2021 |
| 2021-07-06 | VERTEX PHARMACEUTICALS INCORPORATED | $800 | Research payment | Cash or cash equivalent | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic | 2021 | |
| 2021-07-06 | Boston Scientific Corporation | $90 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2021 |
| 2021-07-01 | Mallinckrodt Hospital Products Inc. | $500 | Research payment | Cash or cash equivalent | AN OPEN LABEL EXPANDED ACCESS TREATMENT PROTOCOL FOR VTS-270 (2-HYDROXYPROPYL-CYCLODEXTRIN) IN PATIENTS WITH NEUROLOGIC | 2021 | |
| 2021-06-30 | Travere Therapeutics, Inc. | $10,625 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2021 |
| 2021-06-23 | Regeneron Pharmaceuticals, Inc. | $621 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO < | 2021 |
| 2021-06-23 | Regeneron Pharmaceuticals, Inc. | $621 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO < | 2021 |
| 2021-06-23 | Merge Healthcare Incorporated | $218 | Food and Beverage | Cash or cash equivalent | iCEA Device, Medical Imaging | 2021 | |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $6,520 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $1,223 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $1,200 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $1,200 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $1,152 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $1,093 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $1,093 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $1,059 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $1,059 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $1,053 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $1,028 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $1,028 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $998 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $998 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $916 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $796 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $779 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $779 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $779 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $742 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $737 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $706 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $706 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $706 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $688 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Esperion Therapeutics, Inc. | $688 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-06-22 | Esperion Therapeutics, Inc. | $688 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $682 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $679 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $652 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $652 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $652 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $633 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $597 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $448 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $360 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $348 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $337 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $291 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $291 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $291 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $277 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $243 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-06-22 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $180 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $177 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $121 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $109 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $109 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $109 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $109 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $109 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $109 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $109 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $109 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $109 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $109 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $109 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $109 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-06-22 | Aimmune Therapeutics, Inc. | $109 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
The latest 200 records of 467.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Austin, TX, county Travis County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Austin, TX | County Travis County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 979,539 | 1,330,015 | 30,188,424 |
| Population, 2020 census P1 | 961,855 | 1,290,188 | 29,145,505 |
| Median age B01002 | 34.7 | 35.6 | 35.6 |
| Under 18 B01001 | 18.0% | 20.2% | 25.0% |
| 65 and over B01001 | 10.4% | 11.0% | 13.4% |
| Households B11001 | 456,113 | 583,747 | 10,992,816 |
| Foreign born B05002 | 18.7% | 18.1% | 17.6% |
| Median household income B19013 | $93,658 | $99,611 | $78,476 |
| Median family income B19113 | $128,808 | $131,256 | $94,599 |
| Per capita income B19301 | $62,862 | $62,607 | $40,752 |
| Poverty rate B17001 | 12.0% | 10.9% | 13.8% |
| Unemployment rate B23025 | 4.7% | 4.6% | 5.3% |
| Civilian labor force B23025 | 617,774 | 799,524 | 15,233,563 |
| Mean commute (minutes) B08013 | 23.7 | 25.2 | 26.7 |
| Bachelor's degree or higher B15003 | 59.6% | 56.6% | 33.8% |
| Housing units B25001 | 483,071 | 618,236 | 12,128,515 |
| Owner-occupied B25003 | 43.4% | 52.1% | 62.6% |
| Renters B25003 | 56.6% | 47.9% | 37.4% |
| Median home value B25077 | $555,300 | $523,000 | $283,800 |
| Median gross rent B25064 | $1,729 | $1,744 | $1,403 |
| White, not Hispanic B03002 | 47.0% | 46.9% | 39.1% |
| Black B03002 | 7.3% | 7.8% | 11.9% |
| Hispanic or Latino B03002 | 31.9% | 32.6% | 39.7% |
| Asian B03002 | 9.0% | 7.8% | 5.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Austin, TX.
Comments